Recommendation of the President – Repatha (evolocumab)
On 25 July 2025 the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 94/2025 on the reimbursement of the medicinal product Repatha (evolocumab) under the B.101 drug program. “Treatment of patients with lipid disorders (ICD-10: E78.01, I21, I22, I25)”